We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

76 hedge funds and large institutions have $265M invested in SAB Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

580% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 5

243% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 7

116% more call options, than puts

Call options by funds: $611K | Put options by funds: $283K

95% more capital invested

Capital invested by funds: $136M → $265M (+$129M)

59.46% more ownership

Funds ownership: 76.34% → 135.8% (+59%)

58% more funds holding

Funds holding: 48 → 76 (+28)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
76
Holders Change
+28
Holders Change %
+58.33%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
34
Increased
24
Reduced
7
Closed
5
Calls
$611K
Puts
$283K
Net Calls
+$328K
Net Calls Change
+$328K

Top Buyers

Rank Fund Capital Flow
1
CP
Caligan Partners
New York
+$31.8M
2
PA
Perceptive Advisors
New York
+$22.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$13.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.1M
5
Millennium Management
Millennium Management
New York
+$10.8M

Top Sellers

Rank Fund Capital Flow
1
Blackstone Inc
Blackstone Inc
New York
-$5.12M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$100K
3
ACM
ADAR1 Capital Management
Texas
-$98.5K
4
SAM
Simplify Asset Management
Nevada
-$83.7K
5
Citadel Advisors
Citadel Advisors
Florida
-$70.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Stempoint Capital
New York
$1.44M +$911K +228,442 +156%
HWM
27
HB Wealth Management
Georgia
$1.18M – – –
Geode Capital Management
28
Geode Capital Management
Massachusetts
$1.16M +$728K +182,519 +153%
BlackRock
29
BlackRock
New York
$1.15M +$1.13M +284,087 +1,648%
SGM
30
Seven Grand Managers
New York
$1.05M +$1.1M +275,000 New
VFT
31
Vanguard Fiduciary Trust
Pennsylvania
$757K +$788K +197,619 New
SAM
32
Simplify Asset Management
Nevada
$717K -$83.7K -20,997 -10%
Two Sigma Investments
33
Two Sigma Investments
New York
$694K +$722K +181,185 New
Goldman Sachs
34
Goldman Sachs
New York
$436K +$250K +62,592 +122%
SFCM
35
Seven Fleet Capital Management
California
$383K +$399K +100,000 New
State Street
36
State Street
Massachusetts
$284K +$244K +61,109 +466%
PAP
37
Persistent Asset Partners
Hong Kong
$267K +$199K +49,942 +252%
KAS
38
Kestra Advisory Services
Texas
$236K +$200K +50,191 +435%
BHCM
39
Brevan Howard Capital Management
Jersey
$227K +$236K +59,161 New
Northern Trust
40
Northern Trust
Illinois
$220K +$164K +41,014 +250%
Bank of America
41
Bank of America
North Carolina
$213K +$180K +45,084 +425%
Pathstone Holdings
42
Pathstone Holdings
New Jersey
$194K – – –
SCM
43
Stonepine Capital Management
Oregon
$192K +$199K +50,000 New
UBS Group
44
UBS Group
Switzerland
$179K +$156K +39,225 +530%
FLC
45
Fifth Lane Capital
Texas
$178K +$126K +31,500 +210%
Commonwealth Equity Services
46
Commonwealth Equity Services
Massachusetts
$178K +$185K +46,455 New
VF
47
Virtu Financial
New York
$145K +$151K +37,943 New
American Century Companies
48
American Century Companies
Missouri
$143K +$149K +37,455 New
Citigroup
49
Citigroup
New York
$141K +$27.2K +6,831 +23%
QC
50
Quadrature Capital
United Kingdom
$135K +$141K +35,264 New
1
2
3 4

SABS Hedge Fund Activity: Q1 2026 in Review

76 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2026, worth a combined $265M — up 95% from $136M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new SABS positions and 5 closed out — a net gain of 29 holders — while 24 added to existing stakes and 7 trimmed.

The largest buyer was Caligan Partners, opening a new position worth an estimated $31.8M. The largest seller was Blackstone Inc, cutting an estimated $5.12M.

  • 76 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2026, up from 48 in Q4 2025.
  • Funds reported $265M of SAB Biotherapeutics stock for Q1 2026, up 95% quarter-over-quarter.
  • 34 funds opened new SAB Biotherapeutics positions in Q1 2026 and 5 closed out, a net change of +29 holders.
  • The largest SAB Biotherapeutics buyer in Q1 2026 was Caligan Partners, an estimated $31.8M added.
  • The largest SAB Biotherapeutics seller in Q1 2026 was Blackstone Inc, an estimated $5.12M sold.

Based on aggregated 13F filings for Q1 2026.